Report

Deinove - Cash conservation and operational progress

A refocused business, a strengthened management team and progress with its underlying research programmes suggest Deinove is on course to generate commercial revenues in 2018. Delivery in line with our long-term forecasts would indicate a potential valuation of €4.3/share.
Underlying
Deinove S.A.

Deinove SA is a biotechnology company dedicated to the discovery, development and production of compounds based on the use of rare bacterial genus that present an interest to the health, nutrition and cosmetics sectors.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Graeme Moyse

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch